نتائج البحث

A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens.

• Authors : Xiong, Zhen-Yu^1,2 (AUTHOR); Shen, Yao-Jia³ (AUTHOR); Zhang, Shi-Zhong^1,2 (AUTHOR)

• Source: Hematology. Dec2024, Vol. 29 Issue 1, p1-15. 15p.

تفاصيل العنوان

A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)

• Source: A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia

تفاصيل العنوان

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

• Authors : National Cancer Institute (NCI); Amgen; Takeda

• Source: Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL

تفاصيل العنوان

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

• Authors : EsPhALL; National Cancer Institute (NCI)

• Source: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With

تفاصيل العنوان

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

• Source: A Phase II Study of the Combination of Decitabine, Venetoclax, and Ponatinib in Patients With Philadelphia Chromosome-Positive Acute

تفاصيل العنوان

Secondary Solid Cancers in Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Multicenter Study

• Authors : Hindilerden F; University of Health Sciences Türkiye, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Hematology, İstanbul, Türkiye; Akay ÖN

Subjects: Myeloproliferative Disorders*/Myeloproliferative Disorders*/Myeloproliferative Disorders*/genetics ; Myeloproliferative Disorders*/Myeloproliferative Disorders*/Myeloproliferative Disorders*/epidemiology ; Myeloproliferative Disorders*/Myeloproliferative Disorders*/Myeloproliferative Disorders*/complications

• Source: Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2024 Dec 02; Vol. 41 (4), pp. 246-255. Date of Electronic Publication: 2024 Publisher: Galenos Yayinevi Country of Publication: Turkey NLM ID: 9606065 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Chronic Myeloid Leukemia with a Rare Philadelphia Chromosome Variant Involving Chromosome 16.

• Authors : Bahashwan, Salem M.^1,2

• Source: American Journal of Case Reports. 8/31/2024, Vol. 25, p1-5. 5p.

تفاصيل العنوان

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

• Authors : National Cancer Institute (NCI)

• Source: A Phase I/II Study of the Combination of Venetoclax, Ponatinib and Corticosteroids in Patients With Relapsed or Refractory Philadelphia

تفاصيل العنوان

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)

• Source: A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia

تفاصيل العنوان

Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

• Authors : Novartis Pharmaceuticals

• Source: Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic

تفاصيل العنوان